← Gen Digital Inc. (GEN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Gen Digital Inc. (GEN)
Services-Prepackaged Software · market cap $14.6B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Gen Digital Inc. (GEN) is a large-cap cybersecurity and consumer software company operating brands including Norton, Avast, LifeLock, AVG, Avira, and CCleaner, with ~$5B in annual revenue and a market cap of ~$15.5B. The FACTS data anomalously attributes a clinical-stage probiotic pipeline (Lactobacillus brevis CD2 lozenges in Phase 3 for Chronic Periodontitis and Malocclusion, plus a Phase 2 psoriasis asset GN-037) as GEN's lead assets — these appear to be data errors or misattributions entirely inconsistent with the company's actual business. The dossier reflects GEN as it actually operates: a mature consumer cyber-safety subscription business carrying $7.97B in net debt.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GN-037 | Phase 2 | Psoriasis |
| Lactobacillus brevis CD2 Lozenges | Phase 3 | Chronic Periodontitis |
| Probiotic | Phase 3 | Chronic Periodontitis |
| Probiotic (L. brevis CD2 lozenges) | Phase 3 | Malocclusion |
Price & technical context
3-month
+19.2%
6-month
-14.7%
12-month
-18.2%
52-wk range
$17.89–$32.16
vs 50-day MA
+3.6%
vs 200-day MA
-4.1%
Realized vol
33.4%
Max drawdown
-44.4%
Daily closes through 2026-06-24. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GEN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.